$107.99
1.60% today
Nasdaq, Apr 03, 06:45 pm CET
ISIN
US05464T1043
Symbol
AXSM
Sector
Industry

Axsome Therapeutics, Inc. Stock price

$109.75
-17.40 13.68% 1M
+16.51 17.71% 6M
+25.14 29.71% YTD
+35.19 47.20% 1Y
+63.37 136.63% 3Y
+54.09 97.18% 5Y
+101.01 1,155.72% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
-1.92 1.72%
ISIN
US05464T1043
Symbol
AXSM
Sector
Industry

Key metrics

Market capitalization $5.35b
Enterprise Value $5.24b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 13.58
P/S ratio (TTM) P/S ratio 13.88
P/B ratio (TTM) P/B ratio 93.68
Revenue growth (TTM) Revenue growth 42.53%
Revenue (TTM) Revenue $385.69m
EBIT (operating result TTM) EBIT $-252.44m
Free Cash Flow (TTM) Free Cash Flow $-128.68m
Cash position $315.35m
EPS (TTM) EPS $-6.00
P/E forward negative
P/S forward 8.61
EV/Sales forward 8.43
Short interest 12.03%
Show more

Is Axsome Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Axsome Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a Axsome Therapeutics, Inc. forecast:

17x Buy
100%

Analyst Opinions

17 Analysts have issued a Axsome Therapeutics, Inc. forecast:

Buy
100%

Financial data from Axsome Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
386 386
43% 43%
100%
- Direct Costs 41 41
21% 21%
11%
345 345
46% 46%
89%
- Selling and Administrative Expenses 403 403
28% 28%
105%
- Research and Development Expense 186 186
91% 91%
48%
-245 -245
40% 40%
-63%
- Depreciation and Amortization 7.82 7.82
2% 2%
2%
EBIT (Operating Income) EBIT -252 -252
38% 38%
-65%
Net Profit -287 -287
20% 20%
-74%

In millions USD.

Don't miss a Thing! We will send you all news about Axsome Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Axsome Therapeutics, Inc. Stock News

Negative
The Motley Fool
2 days ago
Shares of biopharmaceutical company Axsome Therapeutics (AXSM -6.29%) had declined 6% at 11 a.m. ET today. The slump comes after the company announced the results of a phase 3 trial of solriamfetol (brand name Sunosi) in major depressive disorder (MDD).
Negative
Investors Business Daily
2 days ago
Axsome Therapeutics posted mixed results for its experimental depression treatment on Tuesday, leading Axsome stock to dive. The post Axsome Therapeutics Dives Again On Its Second Big Drug Failure In A Week appeared first on Investor's Business Daily.
Negative
Reuters
2 days ago
Axsome Therapeutics said on Tuesday its experimental drug to treat major depressive disorder failed to meet the main goal of a late-stage study.
More Axsome Therapeutics, Inc. News

Company Profile

Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its product candidates include AXS-05, AXS-07, AXS-09, AXS-12, and AXS-14 which are developing for multiple pain and primary care indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Head office United States
CEO Herriott Tabuteau
Employees 683
Founded 2012
Website www.axsome.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today